Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.53 |
| ▸ | IKBKB | O14920 | 3/20 | 0.41 |
| ▸ | USP1 | O94782 | 1/20 | 0.41 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171361 | 0.77 | IKBKB (0.46) | IKBKBACP1CHEK1CCNA2CDK2 | |
| SCHEMBL18489932 | 0.73 | CYP11B2 (0.75) | CYP11B2 | |
| SCHEMBL5787962 | 0.72 | ADORA2A (0.48) | IKBKBACP1 | |
| SCHEMBL14339737 | 0.71 | IKBKB (0.48) | IKBKBUSP1WDR48ACP1CHEK1 | |
| SCHEMBL18502901 | 0.70 | CYP11B2 (1.00) | CYP11B2USP1WDR48 | |
| SCHEMBL17207692 | 0.69 | CYP11B2 (0.56) | CYP11B2 | |
| SCHEMBL7470322 | 0.69 | DRD2 (0.44) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL20609687 | 0.69 | DRD2 (0.44) | CHEK1CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL4130390 | 0.68 | S1PR1 (0.51) | — | |
| Hydrochloric Acid SCHEMBL4130385 | 0.68 | S1PR1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | CYP11B2 19/4885IKBKB 1304/4885USP1 1135/4885 |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | NR3C2, REN, CYP21A2 | CYP11B2 17/4885IKBKB 1205/4885USP1 1239/4885 |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | CYP11B2 19/4885IKBKB 1304/4885USP1 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.